Company Analysis
Sign in

Novo-Nordisk A/S (NVO)

NYSE: NVO · Pharmaceutical Preparations · Bagsvaerd Denmark, DK · filing with the SEC since 2001
Full chart Alerts Compare
Grade6.9
◀ Past 8.4● Present 7.0▶ Future 5.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,823 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Novo-Nordisk A/S’s names, not what it holds today.

Patents granted
1,823
1,788 utility, 24 design, 11 reissue, 1976 to Dec 31, 2025
Granted in 2025
30
Against 32 in 2024 and 37 in 2023
Applications published
1,524
40 of them in 2025
Names they are printed under
3
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Medical technology91
Pharmaceuticals68
Biotechnology21
Analysis of biological materials5
Organic fine chemistry3
Materials, metallurgy1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Novo Nordisk A/S its own name
DK, as the owner printed on each patent. 21 more under the same name are not counted (printed in CA, printed in US, printed in DE)
1,813 granted
858 published
Novo Nordisk A/S its own name
named as the applicant on its applications, in DK. 8 more under the same name are not counted (printed in DE, printed in SE, printed in JP)
0 granted
662 published
Novo Nordisk Inc. its own name
DK, as the owner printed on each patent
10 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,675Aminoacyl-tRNA synthetases and uses hereofBiotechnologyNovo Nordisk A/S
Dec 23, 202512,503,701Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expressionBiotechnologyNovo Nordisk A/S
Dec 9, 202512,492,249Antibodies and use thereofAnalysis of biological materialsNovo Nordisk A/S
Dec 2, 202512,485,229Reusable torsion spring driven injection deviceMedical technologyNovo Nordisk A/S
Nov 25, 202512,478,741Drug delivery system with multipolar magnet and sensor systemMedical technologyNovo Nordisk A/S
Oct 7, 202512,433,999Injection device incorporating a needle shield removerMedical technologyNovo Nordisk A/S
Sep 30, 202512,427,264Drug delivery device with plunger rod having nonuniform stopper interfaceMedical technologyNovo Nordisk A/S
Sep 9, 2025D1,092,723Injection deviceNovo Nordisk A/S
Sep 2, 202512,404,500Homing endonuclease variantsBiotechnologyNovo Nordisk A/S
Sep 2, 202512,404,325Anti IL-6 domain antibodies with fatty acid substituentsPharmaceuticalsNovo Nordisk A/S
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387336SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACIDPharmaceuticalsNovo Nordisk A/S
Dec 11, 20252025/0376538BISPECIFIC FACTOR VIII MIMETIC ANTIBODIESBiotechnologyNovo Nordisk A/S
Dec 11, 20252025/0375504SEMAGLUTIDE FOR USE IN MEDICINEPharmaceuticalsNovo Nordisk A/S
Dec 4, 20252025/0368973HOMING ENDONUCLEASE VARIANTSBiotechnologyNovo Nordisk A/S
Oct 30, 20252025/0333496ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTSPharmaceuticalsNovo Nordisk A/S
Oct 30, 20252025/0333418PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOFOrganic fine chemistryNovo Nordisk A/S
Oct 23, 20252025/0325484METHOD AND EQUIPMENT FOR FRACTIONATION OF GRANULES FOR USE IN PHARMACEUTICAL COMPOSITIONSPharmaceuticalsNovo Nordisk A/S
Oct 2, 20252025/0304645Prodrugs of GLP-1 Polypeptide and Uses ThereofPharmaceuticalsNovo Nordisk A/S
Sep 18, 20252025/0290071STAT3 TARGETING OLIGONUCLEOTIDES AND USES THEREOFPharmaceuticalsNovo Nordisk A/S
Sep 18, 20252025/0289898HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINSPharmaceuticalsNovo Nordisk A/S
What it applied for, 2024 to 2025: Pharmaceuticals 46 · Medical technology 22 · Biotechnology 15 · Organic fine chemistry 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NVO · research, not advice